Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SANTA CLARA, Calif., Sept. 15, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the Company will present at the Ladenburg Thalmann Healthcare Conference in New York, NY.
Event: Ladenburg Thalmann 2nd Annual Healthcare Conference
Date: Tuesday, September 27th, 2016
Time: 1:00 p.m. ET
An audio webcast of the Company’s presentation will be available online at www.miramarlabs.com/investors. A replay of the presentation will be available for 90 days.
Investors who are not attending the conference but would like to schedule a one-on-one meeting with Miramar management may do so by contacting Chris Nardo at The Ruth Group at [email protected].
About Miramar Labs:
Miramar Labs, Inc.® is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
Contact: Investors: Brigid Makes Sr. Vice President & CFO Phone: 408.579.8700 Email: [email protected] Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 [email protected] [email protected]
